Smithers Avanza: New lab to support all phases of biotherapeutics development

Smithers-Avanza-New-lab-to-support-all-phases-of-biotherapeutics-development.jpg
(Image: Getty/JK1991) (Getty Images/iStockphoto)

Smithers Avanza’s Bioanalytical Services division is adding 18,500 square feet of laboratory space in New Jersey to support the development of biotherapeutics.

Ira S. DuBey, MS, MBA, PhM, executive vice president, Smithers Avanza Bioanalytical Services, said the location is in close proximity to the company’s clients. There also is a pool of highly educated and experienced talent available in the area, she told us – and the company is currently in the hiring process.

The contract research organization (CRO) will provide bioanalytical testing “to support the development of biotherapeutics from discovery through all phases of development,” DuBey added.

These services include assay development, validation, as well as sample analysis in a GLP-, GCP-, GMP-, and CLIA-certified laboratory. Testing services will include various ligand binding assay platforms, such as ultrasensitive assays, as well as LC/MS/MS, high-resolution mass spectrometry (HRMS), flow cytometry, and quantitative PCR.

Driving demand for these services is the increased development of biotherapeutics and focus on immuno-oncology and personalized medicine, said DuBey.

The expansion is slated to be completed in early 2019.